Evaluating  	Evaluating  	 VBG	O
the  	the  	 DT	O
effects  	effects  	 NNS	O
of  	of  	 IN	O
amantadin 	amantadin 	 NN	B-NP
,  	,  	 ,	O
modafinil  	modafinil  	 NN	B-NP
and  	and  	 CC	O
acetyl-L-carnitine  	acetyl-L-carnitine  	 JJ	B-NP
on  	on  	 IN	O
fatigue  	fatigue  	 NN	O
in  	in  	 IN	O
multiple  	multiple  	 JJ	O
sclerosis--result  	sclerosis--result  	 NN	B-NP
of  	of  	 IN	O
a  	a  	 DT	O
pilot  	pilot  	 NN	O
randomized 	randomized 	 NN	O
,  	,  	 ,	O
blind  	blind  	 JJ	O
study  	study  	 NN	B-NP
Fatigue  	Fatigue  	 NNP	I-NP
affects  	affects  	 VBZ	O
more  	more  	 JJR	O
than  	than  	 IN	O
60 	60 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
multiple  	multiple  	 JJ	B-NP
sclerosis  	sclerosis  	 NNS	I-NP
( 	( 	 -LRB-	O
MS 	MS 	 NNP	B-NP
)  	)  	 -RRB-	O
patients  	patients  	 NNS	O
and  	and  	 CC	O
is  	is  	 VBZ	O
one  	one  	 CD	O
of  	of  	 IN	O
the  	the  	 DT	O
most  	most  	 RBS	O
troublesome  	troublesome  	 JJ	O
symptoms  	symptoms  	 NNS	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
disease 	disease 	 NN	O
.  	.  	 .	O
Current  	Current  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
options  	options  	 NNS	I-NP
for  	for  	 IN	I-NP
MS  	MS  	 NNP	I-NP
fatigue  	fatigue  	 NNS	I-NP
include  	include  	 VBP	O
amantadine 	amantadine 	 VBN	O
,  	,  	 ,	O
modafinil  	modafinil  	 NN	B-NP
and  	and  	 CC	O
acetyl-l-carnitine  	acetyl-l-carnitine  	 NNP	B-NP
( 	( 	 -LRB-	O
ALCAR 	ALCAR 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
aim  	aim  	 NN	O
of  	of  	 IN	O
our  	our  	 PRP$	O
study  	study  	 NN	O
was  	was  	 VBD	O
to  	to  	 TO	O
compare  	compare  	 VB	O
efficacy  	efficacy  	 VBN	O
of  	of  	 IN	O
amantadine 	amantadine 	 NN	B-NP
,  	,  	 ,	O
modafinil  	modafinil  	 NN	B-NP
and  	and  	 CC	O
ALCAR  	ALCAR  	 NNP	B-NP
with  	with  	 IN	O
placebo  	placebo  	 NN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
MS 	MS 	 NNP	B-NP
.  	.  	 .	O
Patients  	Patients  	 NNS	O
with  	with  	 IN	O
MS  	MS  	 NNP	B-NP
and  	and  	 CC	O
a  	a  	 DT	O
disability  	disability  	 NN	B-NP
level  	level  	 NN	I-NP
≤  	≤  	 CD	O
5.5  	5.5  	 CD	O
on  	on  	 IN	O
the  	the  	 DT	O
Kurtzke  	Kurtzke  	 NNP	B-NP
Expanded  	Expanded  	 NNP	I-NP
Disability  	Disability  	 NNP	I-NP
Status  	Status  	 NNP	I-NP
Scale  	Scale  	 NNP	I-NP
( 	( 	 -LRB-	O
EDSS 	EDSS 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
fatigue  	fatigue  	 NNS	O
were  	were  	 VBD	O
included  	included  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
study 	study 	 NN	O
.  	.  	 .	O
Patients  	Patients  	 NNS	O
were  	were  	 VBD	O
assigned  	assigned  	 VBN	O
to  	to  	 TO	O
a  	a  	 DT	O
one  	one  	 CD	O
month  	month  	 NN	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
either  	either  	 DT	O
amantadine  	amantadine  	 JJ	O
200mg 	200mg 	 NN	O
,  	,  	 ,	O
ALCAR  	ALCAR  	 NNP	O
2g 	2g 	 NNP	O
,  	,  	 ,	O
modafinil  	modafinil  	 JJ	O
200mg  	200mg  	 NN	O
or  	or  	 CC	O
placebo 	placebo 	 NN	O
.  	.  	 .	O
Efficacy  	Efficacy  	 NNP	O
of  	of  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
was  	was  	 VBD	O
evaluated  	evaluated  	 VBN	O
by  	by  	 IN	O
using  	using  	 VBG	O
the  	the  	 DT	O
modified  	modified  	 JJ	B-NP
fatigue  	fatigue  	 JJ	I-NP
impact  	impact  	 NN	I-NP
scale  	scale  	 NN	I-NP
( 	( 	 -LRB-	O
MFIS 	MFIS 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Sixty  	Sixty  	 JJ	O
patients  	patients  	 NNS	O
were  	were  	 VBD	O
included  	included  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
study  	study  	 NN	O
( 	( 	 -LRB-	O
39  	39  	 CD	O
females 	females 	 NNS	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
mean  	mean  	 JJ	O
age  	age  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
was  	was  	 VBD	O
38  	38  	 CD	O
±  	±  	 CD	O
6.7  	6.7  	 CD	O
years  	years  	 NNS	O
and  	and  	 CC	O
the  	the  	 DT	O
mean  	mean  	 JJ	O
disease  	disease  	 NN	B-NP
duration  	duration  	 NN	I-NP
was  	was  	 VBD	O
6.6  	6.6  	 CD	O
±  	±  	 CD	O
1.2  	1.2  	 CD	O
years 	years 	 NNS	O
.  	.  	 .	O
Contrast  	Contrast  	 NN	B-NP
analysis  	analysis  	 NN	I-NP
showed  	showed  	 VBD	O
significantly  	significantly  	 RB	O
lower  	lower  	 RBR	O
mean  	mean  	 JJ	O
MFIS  	MFIS  	 NNP	B-NP
score  	score  	 NN	I-NP
after  	after  	 IN	O
one  	one  	 CD	O
month  	month  	 NN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
on  	on  	 IN	O
amantadine  	amantadine  	 VBG	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
placebo  	placebo  	 VB	O
( 	( 	 -LRB-	O
mean  	mean  	 VB	O
difference=17.3 	difference=17.3 	 CD	O
,  	,  	 ,	O
p=0.001 	p=0.001 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
There  	There  	 EX	O
was  	was  	 VBD	O
also  	also  	 RB	O
a  	a  	 DT	O
trend  	trend  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
lower  	lower  	 JJR	O
MFIS  	MFIS  	 JJ	B-NP
score  	score  	 NN	I-NP
in  	in  	 IN	O
ALCAR  	ALCAR  	 NNP	B-NP
group  	group  	 NN	I-NP
in  	in  	 IN	O
comparison  	comparison  	 NN	O
to  	to  	 TO	O
placebo  	placebo  	 VB	O
( 	( 	 -LRB-	O
mean  	mean  	 VB	O
difference=12.4 	difference=12.4 	 CD	O
,  	,  	 ,	O
p=0.05 	p=0.05 	 NNP	O
,  	,  	 ,	O
with  	with  	 IN	O
Keppel-corrected  	Keppel-corrected  	 JJ	B-NP
alpha  	alpha  	 NN	I-NP
of  	of  	 IN	O
0.046 	0.046 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
quality  	quality  	 NN	O
of  	of  	 IN	O
life  	life  	 NN	O
measured  	measured  	 VBN	O
as  	as  	 IN	O
SF  	SF  	 NNP	B-NP
36  	36  	 CD	O
-  	-  	 :	O
PCS  	PCS  	 NNP	B-NP
and  	and  	 CC	O
SF  	SF  	 NNP	B-NP
36  	36  	 CD	O
-  	-  	 :	O
MCS  	MCS  	 NNP	B-NP
proved  	proved  	 VBD	O
to  	to  	 TO	O
be  	be  	 VB	O
significantly  	significantly  	 RB	O
influenced  	influenced  	 VBN	O
by  	by  	 IN	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
One  	One  	 CD	O
month  	month  	 NN	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
amantadine  	amantadine  	 JJ	B-NP
improved  	improved  	 JJ	I-NP
fatigue  	fatigue  	 NN	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
relapsing-remitting  	relapsing-remitting  	 NNP	O
MS  	MS  	 NNP	B-NP
as  	as  	 RB	O
evaluated  	evaluated  	 VBN	O
by  	by  	 IN	O
MFIS 	MFIS 	 NNP	B-NP
.  	.  	 .	O
No  	No  	 RB	O
or  	or  	 CC	O
only  	only  	 RB	O
a  	a  	 DT	O
trend  	trend  	 NN	O
of  	of  	 IN	O
improvement  	improvement  	 NN	O
was  	was  	 VBD	O
seen  	seen  	 VBN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
modafinil  	modafinil  	 NN	B-NP
or  	or  	 CC	O
ALCAR 	ALCAR 	 NNP	B-NP
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
